Your browser doesn't support javascript.
loading
Do barrier dressings reduce cardiac implantable device infection: Protocol for a randomized controlled trial (BARRIER-PROTECT).
Aydin, Alper; Golian, Mehrdad; Klein, Andres; Redpath, Calum; Davis, Darryl R; Ramirez, Daniel F; Nair, Girish M; Green, Martin; Sadek, Mouhannad; Nery, Pablo B; Hansom, Simon P; Corrales-Medina, Vicente; Wells, George A; Birnie, David H.
Afiliação
  • Aydin A; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Golian M; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Klein A; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Redpath C; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Davis DR; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Ramirez DF; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Nair GM; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Green M; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Sadek M; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Nery PB; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Hansom SP; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Corrales-Medina V; Division of Infectious Diseases, Department of Medicine, University of Ottawa, and The Ottawa Hospital, Canada.
  • Wells GA; Division of Cardiology, University of Ottawa Heart Institute, Canada.
  • Birnie DH; Division of Cardiology, University of Ottawa Heart Institute, Canada.
Heliyon ; 9(12): e22229, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38046145
ABSTRACT

Background:

Cardiac implantable electronic device (CIED) procedures can be associated with serious complications, including infection with significant mortality and morbidity, necessitating removal of the device and prolonged hospitalization. One potential pathophysiological mechanism is pocket contamination at the time of device implantation. Therefore, steps taken to prevent contamination at this stage can potentially reduce CIED infections.The barrier dressing, an adhesive material applied to the skin, has the potential to reduce the colonization of the surgical site with host flora that can predispose to infection. There are a limited number of randomized prospective studies on barrier dressing use during various surgeries, but it has never been systematically studied in CIED implantation.

Objectives:

Do Barrier Dressings Reduce Cardiac Implantable Device Infection? (BARRIER-PROTECT trial; NCT04591366) is a single-centre, prospective, double-armed, single-blinded, randomized controlled trial designed to evaluate the use of an intra-operative adhesive barrier dressing to reduce the risk of end-of-procedure pocket swab positivity. We hypothesize that adhesive draping during implant procedures will reduce the risk of contamination from the skin flora. Also, we aim to investigate if the end-of-procedure pocket swab culture positivity can be used as a potential surrogate marker of CIED infection. Methods and

Design:

Patients undergoing a second or later procedure on the same device pocket (pulse generator change, lead/pocket revision or upgrade) will be enrolled. Eligible and consenting patients will be equally randomized to the use of barrier dressing or not using an automated web-based system. Patients, but not the operator, will be blinded to the arm. The person performing the pocket swabs will also be blinded. The primary endpoint is the end-of-procedure pocket swab culture positivity. The main secondary endpoint is the CIED infection rate.

Discussion:

This is the first randomized controlled trial to assess the effectiveness of using a barrier adhesive draping on reducing the end-of-procedure pocket swab culture positivity. In this study, we are exploring a low-cost intervention that may significantly reduce CIED infection. Also, having a valid surrogate marker for CIED infection at the time of implant will facilitate design of future clinical trials.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_doencas_transmissiveis Idioma: En Revista: Heliyon Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_doencas_transmissiveis Idioma: En Revista: Heliyon Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá
...